公开(公告)号：US20220017516A1

公开(公告)日：2022-01-20

申请号：US17293970

申请日：2019-11-15

Applicant: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

Inventor： Mohammed ALJARAH ,  Dan NICULESCU-DUVAZ ,  Leo LEUNG ,  Deborah SMITHEN ,  Michael BROWN ,  Lawrence Christopher DAVIES ,  Caroline SPRINGER

IPC: C07D471/08 ,  C07D487/08 ,  C07D295/088 ,  C07D487/04 ,  C07D239/48 ,  C07D295/108 ,  C07D487/10 ,  A61P35/00

Abstract: The disclosure relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, Formula (I) as defined herein. Compounds according to Formula I are pharmacologically effective as lysyl oxidase (LOX) inhibitors and are believed to be useful in the treatment of, for instance, cancer.

公开(公告)号：US20210238179A1

公开(公告)日：2021-08-05

申请号：US16972335

申请日：2019-06-05

Applicant: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

Inventor： Leo LEUNG ,  Kiri NORTH ,  Deborah SMITHEN ,  Mohammed ALJARAH ,  Michael BROWN ,  Ben AYERS ,  Dan NICULESCU-DUVAZ ,  Caroline SPRINGER

IPC: C07D487/04 ,  A61P35/00

Abstract: The disclosure relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein X1 and X5 is each selected from CR1 or N; X2, X3 and X4 is each selected from CR1, CR2 or N, provided at least one of X2, X3 and X4 is CR2 and provided only one of X1, X2, X3, X4 and X5 can be N. R1, R2, R3, R4, R5, L1, L2 and L3 are as defined herein. Compounds according to Formula (I) are pharmacologically effective as lysyl oxidase (LOX) inhibitors and are believed to be useful in the treatment of, for instance, cancer.